Age-related macular degeneration, or AMD, affects the macula, the small central region of the retina responsible for the fine detail vision needed for reading, driving, and recognizing faces. While the neovascular form of the disease, characterized by abnormal blood vessel growth under the retina, can be partially managed with injections that suppress vessel growth, a substantial fraction of patients progress to subretinal fibrosis. In this stage, the tissue beneath the retina becomes stiffened by excessive deposits of extracellular matrix proteins, forming scars that permanently destroy photoreceptors and the vision they support. No approved therapy currently reverses or reliably halts this scarring, making it one of ophthalmology’s most urgent unmet needs.

At the heart of the new study is the retinal pigment epithelium, or RPE, a single layer of pigmented cells that sits just behind the photoreceptors and performs the metabolic heavy lifting that keeps them alive. The RPE is among the most metabolically demanding tissues in the body, and its decline with age is considered a core driver of AMD. The research team, led by Xiaowei Yang, Shenglai Zhang, and Yan Wang of Nantong University and collaborating institutions in China, began by examining human AMD specimens and a mouse model of accelerated aging induced by D-galactose, a sugar that when administered chronically produces many hallmarks of natural aging. In both settings, they found that LAPTM5, a protein embedded in lysosomal membranes, was significantly elevated, and that its levels tracked with gene-expression signatures of RPE senescence and fibrogenesis.

To determine whether LAPTM5 was merely a bystander or an active participant in the disease process, the researchers conducted gain- and loss-of-function experiments, artificially increasing or decreasing the protein’s abundance in RPE cells. The results were unambiguous. When LAPTM5 was overexpressed, RPE cells displayed the classic features of senescence: they stopped dividing, accumulated damage markers, and began secreting a potent cocktail of inflammatory and remodeling factors known collectively as the senescence-associated secretory phenotype, or SASP. Conversely, reducing LAPTM5 blunted these senescence programs. This established LAPTM5 as a genuine regulatory driver of RPE aging rather than a passive correlate.

The mechanistic core of the paper lies in what LAPTM5 does to two downstream partners. The team demonstrated that LAPTM5 physically interacts with WWP2, an E3 ubiquitin ligase, and shepherds it toward lysosome-dependent degradation. WWP2, in turn, normally attaches polyubiquitin chains to optineurin, or OPTN, a well-characterized autophagy receptor. Ubiquitinated OPTN is what allows damaged mitochondria to be recognized and engulfed by autophagosomes in a selective process called mitophagy. With WWP2 destroyed, OPTN loses its ubiquitin tags, mitophagy falters, and damaged mitochondria pile up inside the cell. The authors showed that this disruption affected both K48- and K63-linked ubiquitin chains on OPTN, effectively dismantling the quality-control system that aging RPE cells depend on to keep their mitochondrial fleet in working order.

The consequences of this mitochondrial breakdown extend far beyond energy metabolism. When mitophagy fails, the outer and inner membranes of compromised mitochondria become permeable, and fragments of mitochondrial DNA escape into the cytoplasm. To the cell’s surveillance systems, this cytosolic DNA looks exactly like a viral invasion. The cGAS enzyme detects the stray DNA and produces a signaling molecule that activates STING, an adaptor protein on the endoplasmic reticulum that ignites a sustained innate immune response. The researchers documented precisely this sequence: cytoplasmic mitochondrial DNA leakage and persistent cGAS-STING activation in LAPTM5-overexpressing cells, which in turn fueled the massive SASP release that characterizes senescent RPE.

That SASP is where the fibrosis story comes together. The inflammatory factors secreted by senescent RPE cells do not act in isolation; they signal to neighboring cells in a paracrine fashion. According to the study’s model, these signals drive adjacent RPE cells, fibroblasts, choroidal endothelial cells, and macrophages to transdifferentiate into myofibroblasts, the collagen-producing cells that build fibrotic scar tissue. RPE cells themselves undergo epithelial-mesenchymal transition, abandoning their supportive identity and adopting a matrix-secreting, migratory phenotype. The authors note that the paracrine signaling and downstream fibrotic events in this model are inferred from the published literature rather than fully validated experimentally in this study, an important caveat that future work will need to address directly.

The translational experiments provide the study’s most exciting results. Using an adeno-associated virus vector to specifically knock down Laptm5 in the RPE of aged mice, the team achieved a marked reduction in subretinal fibrotic lesions, demonstrating that the protein is not just a marker but a druggable point of intervention. In parallel, the researchers tested H-151, a pharmacological inhibitor of STING, and found that blocking the inflammatory arm of the cascade significantly attenuated the progression of epithelial-mesenchymal transition. Together, these two approaches validate both the upstream trigger and the downstream inflammatory amplifier of the pathway as viable therapeutic targets, offering a rare dual-entry point into a disease process that has resisted treatment for decades.

The identification of LAPTM5 as a senescence regulator also fits into a broader and rapidly expanding picture of how lysosomal dysfunction and innate immune activation conspire to drive aging across tissues. Recent work has implicated the cGAS-STING axis in fibrotic disease of the kidney, lung, and heart, and mitophagy failure has emerged as a recurring theme in neurodegeneration and cardiovascular aging. LAPTM5 itself has previously been linked to inflammatory signaling in macrophages, STING-mediated inflammation in rosacea, tubular senescence in chronic kidney disease, and poor outcomes in several cancers. The new study extends this portfolio to the eye and, crucially, supplies the missing mechanistic link explaining how a lysosomal protein can connect mitochondrial quality control to immune activation and tissue scarring.

Significant work remains before these findings reach the clinic. The study relied heavily on a D-galactose-induced aging model, which accelerates certain aging phenotypes but does not fully recapitulate the decades-long, multifactorial development of human AMD, and the paracrine steps connecting SASP release to myofibroblast formation remain partly inferential. Delivering gene-silencing therapies to the RPE also poses practical challenges, even though the subretinal space is one of the more accessible targets for AAV-based ocular gene therapy. Still, the demonstration that a single lysosomal protein sits atop a cascade connecting senescence, mitophagy, innate immunity, and fibrosis gives researchers a coherent framework for intervention, and for the growing population of patients facing fibrotic AMD, it transforms a seemingly irreversible process into a pathway with identifiable, and potentially blockable, molecular checkpoints.

Subject of Research: The role of the LAPTM5-WWP2-OPTN mitophagy cascade and cGAS-STING signaling in retinal pigment epithelium senescence and subretinal fibrosis in age-related macular degeneration

Article Title: LAPTM5 correlates with RPE senescence and subretinal fibrosis through the LAPTM5-WWP2-OPTN mitophagy cascade and cGAS/STING activation in a D-galactose-induced aging model

Article References: Yang, X., Zhang, S., Wang, Y., Shi, J., Li, W., Lou, X., Yu, Y., Zhang, J., & Sang, A. (2026). LAPTM5 correlates with RPE senescence and subretinal fibrosis through the LAPTM5-WWP2-OPTN mitophagy cascade and cGAS/STING activation in a D-galactose-induced aging model. GeroScience. https://doi.org/10.1007/s11357-026-02506-2

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02506-2

Keywords: age-related macular degeneration, retinal pigment epithelium, LAPTM5, mitophagy, optineurin, WWP2, cGAS-STING, cellular senescence, SASP, subretinal fibrosis, epithelial-mesenchymal transition, GeroScience

Subretinal fibrosis is the body’s wound-healing response gone awry in the confined space between the retinal pigment epithelium and the photoreceptors. When abnormal choroidal blood vessels invade the subretinal space in neovascular AMD, bleeding, inflammation and vascular endothelial growth factor–driven remodeling follow. The retinal pigment epithelial (RPE) cells that normally act as quiet, polarized guardians of the photoreceptor layer respond by abandoning their identity: they lose tight junctions, reorganize their cytoskeleton, and transform into migratory, contractile, matrix-secreting cells. This process, epithelial-mesenchymal transition, or EMT, is driven centrally by transforming growth factor-beta (TGF-β) signaling and produces the collagen-rich scar that physically distorts and eventually destroys the overlying retina.

The research team, led by corresponding authors Chaoyang Zhang, Xiufeng Zhong, Haibin Tian and Jingfa Zhang, with first authors Xi Wang and Xueying Wang, reasoned that a molecule already known to suppress fibrosis in other organs could be repurposed for the eye. Sophocarpine has previously shown anti-fibrotic activity in hepatic and pulmonary models, and its alkaloid chemistry suggested a small molecule capable of crossing biological membranes and reaching intracellular targets. What remained entirely unknown was whether it could do anything for ocular fibrosis—and whether it could do so without harming the delicate neural retina it would have to coexist with.

The safety question came first, and the answer was reassuring. The investigators injected sophocarpine intravitreally into C57BL/6J mice at a concentration of 200 micromolar and then interrogated retinal function with electroretinography, a technique that measures the summed electrical responses of photoreceptors and inner retinal neurons to light flashes. Histological examination of the treated retinas found no detectable acute toxicity. That combination—a preserved electroretinographic waveform and an intact retinal architecture—is the basic license a compound needs before it can be considered seriously for intravitreal delivery, and many candidates never clear that bar.

With safety established, the team moved to a disease model that has become the standard for studying the fibrotic sequelae of neovascular AMD: laser-induced choroidal neovascularization. Focused laser burns to the mouse Bruch’s membrane trigger the growth of abnormal choroidal vessels into the subretinal space, followed by fibrotic scarring that closely mirrors the human lesion. When sophocarpine was delivered into the eyes of these mice, the CNV lesions shrank measurably, collagen deposition within the lesions decreased, and—critically—the co-localization of alpha-smooth muscle actin with RPE65, a marker of RPE cells that had acquired myofibroblast characteristics, was reduced. In plain terms, the RPE cells at the lesion edge were less inclined to become scar-forming cells.

The cellular mechanism was then dissected in culture using two complementary human RPE systems: the widely used ARPE-19 cell line and induced pluripotent stem cell–derived RPE cells, which recapitulate native RPE biology more faithfully. When these cells were stimulated with TGF-β1, they predictably ramped up the mesenchymal program: fibronectin, alpha-smooth muscle actin and vimentin all rose, while the tight-junction protein ZO-1, a hallmark of the healthy epithelial state, was lost. Sophocarpine treatment reversed this cascade. It suppressed the induction of fibronectin, α-SMA and vimentin, preserved ZO-1 expression, and curtailed the functional consequences of EMT—cell migration measured in wound-healing and Transwell assays, and the contractile behavior that scars use to wrinkle and detach the retina, captured in gel contraction assays. The findings were confirmed at transcript, protein and cellular localization levels using quantitative PCR, Western blotting and immunofluorescence.

The mechanistic heart of the paper lies in a striking signaling selectivity. TGF-β signals through two major intracellular routes: the canonical Smad pathway, in which Smad2 and Smad3 transcription factors are phosphorylated and carry the signal to the nucleus, and the non-canonical MAPK pathways, including the MEK/ERK cascade and p38 MAPK. Sophocarpine preferentially reduced the phosphorylation of MEK, ERK and p38 while leaving Smad2/3 phosphorylation untouched. This dissociation is significant because it suggests the compound does not blunt TGF-β signaling wholesale—which could interfere with the many homeostatic roles TGF-β plays in the eye—but instead specifically interrupts the MAPK arm that drives EMT-associated proliferation, migration and matrix production.

To probe how sophocarpine might achieve that selectivity at the molecular level, the team turned to computational structural biology. Molecular docking predicted that the alkaloid fits into binding pockets on MEK1, MEK2 and ERK2, the kinase pair that constitutes the canonical MAPK relay, and molecular dynamics simulations suggested the docked complexes remain stable over simulated time. These are predictive, not definitive, results—binding in silico must ultimately be validated with direct biophysical measurements and target-engagement assays in cells—but they furnish a concrete, testable hypothesis: that sophocarpine acts as a direct inhibitor of upstream MAPK kinases, thereby explaining both the reduced ERK and p38 phosphorylation and the suppression of the EMT program downstream.

The translational implications are considerable. Anti-VEGF therapy, the current mainstay for neovascular AMD, suppresses vascular leakage and growth but does nothing to stop the fibrovascular scar once it begins to organize; a substantial fraction of treated patients develop subretinal fibrosis and irreversible vision loss despite flushes of injections. A molecule that targets the fibrotic arm of the disease—by preserving RPE identity and restraining the TGF-β–MAPK–EMT axis—would address a therapeutic void that no approved drug currently fills. It would also be an unusually accessible candidate: sophocarpine is a defined small molecule with a long history of human exposure in herbal preparations, which could streamline preclinical development compared with entirely novel chemical entities.

That said, the distance from a laser-burn mouse and a culture dish to a clinic-ready therapy remains long. The study used a single dose level for the intravitreal safety assessment, relied on an acute injury model rather than spontaneous, slowly evolving human fibrosis, and its mechanistic target hypothesis awaits confirmation with techniques such as surface plasmon resonance and kinase assays. The authors themselves position sophocarpine as a promising preclinical candidate that warrants further investigation. Even so, the convergence of findings—in vivo reduction of scarring, in vitro reversal of EMT, and a coherent signaling rationale—makes this one of the more complete early-stage stories in ocular fibrosis research, and a reminder that some of ophthalmology’s next tools may still come from plants that traditional medicine has used for centuries.

Subject of Research: Therapeutic inhibition of subretinal fibrosis and retinal pigment epithelial EMT by the plant-derived alkaloid sophocarpine

Article Title: Sophocarpine, a bioactive alkaloid derived from Sophora flavescens, alleviates subretinal fibrosis by suppressing epithelial-mesenchymal transition

Article References: Sophocarpine, a bioactive alkaloid derived from Sophora flavescens, alleviates subretinal fibrosis by suppressing epithelial-mesenchymal transition. (n.d.). https://doi.org/10.1186/s12967-026-08995-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08995-1

Keywords: sophocarpine, Sophora flavescens, subretinal fibrosis, neovascular age-related macular degeneration, retinal pigment epithelium, epithelial-mesenchymal transition, TGF-beta, MEK/ERK, p38 MAPK, choroidal neovascularization, anti-fibrotic therapy, Journal of Translational Medicine